43 related articles for article (PubMed ID: 38625861)
1. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
Li H; Huntington S; Gross C; Wang SY
PLoS One; 2024; 19(4):e0300789. PubMed ID: 38625861
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
5. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
6. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
7. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
Kehl KL; Hassett MJ; Schrag D
Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
[TBL] [Abstract][Full Text] [Related]
8. Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy.
Han CY; Fitzgerald C; Lee M; Valero C; Gönen M; Shoushtari A; Morris LGT
JAMA Oncol; 2022 Sep; 8(9):1352-1354. PubMed ID: 35797031
[TBL] [Abstract][Full Text] [Related]
9. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
Fountzilas E; Lampaki S; Koliou GA; Koumarianou A; Levva S; Vagionas A; Christopoulou A; Laloysis A; Psyrri A; Binas I; Mountzios G; Kentepozidis N; Kotsakis A; Saloustros E; Boutis A; Nikolaidi A; Fountzilas G; Georgoulias V; Chrysanthidis M; Kotteas E; Vo H; Tsiatas M; Res E; Linardou H; Daoussis D; Bompolaki I; Andreadou A; Papaxoinis G; Spyratos D; Gogas H; Syrigos KN; Bafaloukos D
Cancer Immunol Immunother; 2022 Feb; 71(2):327-337. PubMed ID: 34164709
[TBL] [Abstract][Full Text] [Related]
10. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
11. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Rini BI; Battle D; Figlin RA; George DJ; Hammers H; Hutson T; Jonasch E; Joseph RW; McDermott DF; Motzer RJ; Pal SK; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2019 Dec; 7(1):354. PubMed ID: 31856918
[TBL] [Abstract][Full Text] [Related]
12. To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
Pantuck M; McDermott D; Drakaki A
Cancer; 2019 Oct; 125(20):3506-3513. PubMed ID: 31318445
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
14. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.
Nixon NA; Blais N; Ernst S; Kollmannsberger C; Bebb G; Butler M; Smylie M; Verma S
Curr Oncol; 2018 Oct; 25(5):e373-e384. PubMed ID: 30464687
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
